Financhill
Back

ADMA Biologics Quote, Financials, Valuation and Earnings

2025 Gold Forecast: A Perfect Storm for Demand

Discover our Gold Price Outlook for 2025--FREE--here
Buy
60

ADMA
ADMA Biologics

Last Price:
$17.44
Seasonality Move:
2.93%

7 Day Trial

ALL ACCESS PASS

$ 7

The AI Energy Miracle

Details Here.

ADMA Biologics Price Quote

$17.44
+0.04 (+-2.57%)
(Updated: December 21, 2024 at 5:13 AM ET)

ADMA Biologics Key Stats

Buy
60
ADMA Biologics (ADMA) is a Buy

Day range:
$17.08 - $17.96
52-week range:
$4.16 - $23.64
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
10.79
P/B ratio:
17.74%

Volume:
6.9M
Avg. volume:
3.1M
1-year change:
325.43%
Market cap:
$4.1B
Revenue:
$258.2M
EPS:
$0.28

How Much Does ADMA Biologics Make?

Data Unavailable

Is ADMA Biologics Growing As A Company?

Data Unavailable

ADMA Biologics Stock Price Performance

  • Did ADMA Biologics Stock Go Up Last Month?
    ADMA Biologics share price went down by -18.58% last month
  • Did ADMA's Share Price Rise Over The Last Year?
    ADMA share price rose by 325.43% over the past 1 year

What Is ADMA Biologics 52-Week High & Low?

ADMA Biologics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy ADMA Biologics?

Data Unavailable

Is ADMA Biologics Cash Flow Positive?

Data Unavailable

ADMA Biologics Return On Invested Capital

Data Unavailable

ADMA Biologics Earnings Date & Stock Price

ADMA Biologics Competitors

  • Who Are ADMA Biologics's Competitors?
    Below is a list of companies who compete with ADMA Biologics or are related in some way:
    • Alnylam Pharmaceuticals Inc (ALNY)
    • Corcept Therapeutics Inc (CORT)
    • Catalyst Pharmaceuticals Inc (CPRX)
    • Krystal Biotech Inc (KRYS)
    • Sarepta Therapeutics Inc (SRPT)

ADMA Biologics Dividend Yield

Data Unavailable

ADMA Biologics Analyst Estimates

YoY Growth Past Surprise
EPS: 1400% 15.39%
Revenue: 78.13% 13.22%

Analyst Recommendations

Buy Recommendations: 4
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 24.25
Upside from Last Price: 39.34%

Major Shareholders

Data Unavailable